Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is ALXN's Operating Cash Flow?

  Alexion Pharmaceuticals Inc ( ALXN ) |
1995 - 2021 (27 years)

Operating Cash Flow is 
$3.2B (1Y +28.1% )

ALXN Stock Price & Operating Cash Flow

Operating Cash Flow for ALXN competitors.
CELG GILD REGN VRTX BIIB AGIO RARE IONS QGEN XON
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Operating Cash Flow

chevron_right 2021 $840.5M +493x *
( +25.8% / year avg)
chevron_left 1995 -$1.7M
vertical_align_top Peak $2.7B +19.3x *
vertical_align_bottom Bottom -$146.2M
arrow_drop_up # Up Years 18 18 of 27
years up.
arrow_drop_down # Down Years 9
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • ALXN's stock price has rallied +4,601% from $2.31 in 1995 , or -0.09x the rate relative to it's operating cash flow over the same period.
  • If ALXN grows it's stock at the same rate as it's operating cash flow (+25.8%/year) , it's stock price will grow +992% and hit $1079.23 over the next 10 years.
  • ALXN's stock price has gone up 0 of the 18 years (0%) it's operating cash flow were also up.
* A modified method (see: here) is used to calculate changes that involve negative numbers.
  • ALXN Historical Operating Cash Flow Table
    in $ million
    * A modified method (see: here) is used to calculate changes that involve negative numbers.
    Year Operating Cash Flow YoY % Change* Stock Price YoY % Change (Stock Price)
    4/1/2021 $840 -68.6% - -
    4/1/2020 $2,679 62.3% - -
    4/1/2019 $1,651 175.1% - -
    4/1/2018 $600 -51.6% - -
    4/1/2017 $1,240 105.8% - -
    4/1/2016 $602 -21.5% - -
    4/1/2015 $767 35.8% - -
    4/1/2014 $565 43.7% - -
    4/1/2013 $393 -0.8% - -
    4/1/2012 $396 72.1% - -
    4/1/2011 $230 61.8% - -
    4/1/2010 $142 26.8% - -
    4/1/2009 $112 11892.3% - -
    4/1/2008 $0 -100.6% - -
    4/1/2007 $-146 44.8% - -
    4/1/2006 $-100 -6.8% - -
    4/1/2005 $-108 53.3% - -
    4/1/2004 $-70 -18.0% - -
    4/1/2003 $-86 37.8% - -
    4/1/2002 $-62 165.7% - -
    4/1/2001 $-23 42.4% - -
    4/1/2000 $-16 50.2% - -
    4/1/1999 $-11 -16.0% - -
    4/1/1998 $-13 445.8% - -
    4/1/1997 $-2 -52.9% - -
    4/1/1996 $-5 200.0% - -
    4/1/1995 $-1 - - -

  • About
    Industry: Biotechnology
    Sector: Healthcare
    Country: US
    IPO Date: 2/1/1996
    Stonk Exchange: NASDAQ
    • Alexion Pharmaceuticals, Inc
    • is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
    • The company is headquartered in Boston, Massachusetts and currently employs 2,656 full-time employees.
    • The firm is focused on the development and commercialization of therapeutic products.
    • The firm's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
    • The firm's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
    • Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS).
    • PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system.
    • Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP).
    • Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D).
    • The company is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

  • Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations, otherwise, it may require external financing for capital expansion.

    For more detailed definitions, please see Investopedia.